E39 peptide vaccine
DRACPC ID DRACPC0102
Active Ingredients E39 peptide vaccine
Description A cancer vaccine comprised of human leukocyte antigen (HLA) A2 restricted folate binding protein (FBP) epitope E39 (amino acids 191 to 199), with potential immunostimulatory and antineoplastic activity. Upon intradermal injection, FBP E39 peptide vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against FBP-expressing tumor cell types. FBP is a membrane-bound, tumor-associated antigen highly overexpressed in various tumor cell types, such as in breast, ovarian and endometrial cancers; E 39 is a strong immunogenic peptide.
Synonyms FBP E39 Peptide Vaccine; Folate Binding Protein E39 Peptide Vaccine; E39 Peptide Vaccine
Type Biotech
Disease Breast Cancer, Ovarian Cancer
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula Not available
Molecular Weight Not available
Active Sequence EIWTHSYKV
Sequence Length 9
Modification Not available
Structure
IUPAC Name Not available
InChI Not available
InChI_Key Not available
SMILES Not available
External Codes
PubChem CID Not available
DrugBank Accession Number Not available
NCI Thesaurus Code C101530
UNII Not available
CAS Not available
Drug approval
Drug indication
Investigated for use/treatment in Breast Cancer, Ovarian Cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT02019524 | Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients | Breast Cancer; Ovarian Cancer | Phase 1 | Treatment |
| NCT01580696 | Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients | Ovarian Cancer; Endometrial Cancer; Fallopian Cancer; Peritoneal Cancer | Phase 1/2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
